Early in 2024 Chr. Hansen and Novozymes joined forces to form Novonesis, a company with its headquarters in Denmark, employing 10,000 people worldwide. Their expertise spans more than 30 different industries. Novonesis’ biosolutions enable feeding and fueling the world more sustainably, from healthy and sustainable nutrition to biofuel. Our microbes and enzymes also reduce the use of fossil-based resources, chemicals, energy, and water.

Founded in 2018, Meatable is a rapidly growing, well funded, mission driven alternative protein scale-up that uses proprietary stem cell technology designed to manufacture cultured meat.

Oterra specializes in the development and production of natural coloring ingredients for food and beverages. EQT owned Oterra is a former subsidiary of Chr. Hansen.

Novozymes is the global market leader in biological solutions, producing a wide range of industrial enzymes and microorganisms for a broad range of industries. The company is one of the C20 companies listed at the Danish stock exchange.

Mediq is the Advent International owned distributor of medical devices and care solutions, both at home and institutional. The company's main activities are in North West Europe.

ForFarmers is a Euronext Amsterdam listed animal feed company with sales of c. EUR 2 bio. ForFarmers is a market leader in Europe.

Chr. Hansen is a global supplier of bioscience-based ingredients to the food, health and animal feed industries. Using a few common technology platforms the company mainly produces cultures and dairy enzymes, natural colors, and probiotics, and has leading positions in most of its markets. Chr. Hansen is listed on the NASDAQ OMX Copenhagen Stock Exchange as a C20 companyTogether with a largely new team delivered the 'Nature's No. 1' strategy and realized on average 10% organic growth per annum. Increased EBIT and tripled the market cap to well over EUR 10 bio.

Through ‘hands-on’ responsibility for most of the company’s functions, co-led the organization through the transformation process to become a fully integrated Bio-Pharmaceutical company. Revenue grew with more than 25% every year, and contributed significantly to turning the company profitable one year ahead of analyst expectations.

Turned around a troubled very complex business and created significant shareholder value by improving customer service, eliminating non-value-adding activities including bolt off divestment of non-core assets.